Annual General Meeting of Q-Med AB

UPPSALA, Sweden, March 23, 2005 (PRIMEZONE) -- The Board of Directors in Q-Med AB (publ) has of today announced a notice to attend the Annual General Meeting, which will be held on Thursday April 28 at 5 p.m. on Q-Med's premises. Entrance from Fyrisvallsgatan 7, Uppsala, Sweden. A notice has been published in Upsala Nya Tidning and Svenska Dagbladet and will on Thursday March 24 again be published in the above mentioned newspapers with correct date as well as in Post- och Inrikes Tidningar. The complete notice of the Annual General Meeting can be found on the corporate web site:, and is also enclosed.

Queries should be addressed to:

Anne Rhenman, Director Investor Relations and Corporate Communications Tel: 070-974 90 15

Note: Q-Med AB operates under the name of Q-Med Scandinavia, Inc. in the USA.

Q-Med is a rapidly growing and profitable biotechnology/medical device company that develops, produces, markets and sells medical implants. All products are based on the company's patented NASHA technology - Non-Animal Stabilized Hyaluronic Acid. The products covered by the RESTYLANE trademark are used for the filling out of lips and facial wrinkles and for facial contouring and today account for the majority of sales. RESTYLANE is sold in over 70 countries and has been approved in the USA. DUROLANE, Q-Med's product for the treatment of osteoarthritis of the hip and knee joints, has been approved in Europe since May 2001. DEFLUX is a product which has been approved in Europe and the USA for the treatment of vesicoureteral reflux (malformation of the urinary bladder) in children. ZUIDEX for the treatment of stress urinary incontinence in women has been sold in Europe since July 2002. Q-Med today has 540 employees, with approximately 350 at the company's production facility and head office in Uppsala. The Q-Med share is listed on the O- list of the Stockholm Stock Exchange, Attract 40.

This information was brought to you by Waymaker

The following files are available for download: